Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
| Novavax to Host Conference Call to Discuss Second Quarter Financial Results on August 10, 2015 | ||||||||||||||||||
| By: Nasdaq / GlobeNewswire - 03 Aug 2015 | Back to overview list |
|||||||||||||||||
GAITHERSBURG, Md., Aug. 03, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced it will report its second quarter 2015 financial and operating results after the close of U.S. financial markets on Monday, August 10, 2015. In addition, management will host a conference call to discuss the quarterly results and provide an update on corporate activities.
Conference call details are as follows:
Conference call replay:
About Novavax Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M(TM) adjuvant technology are the foundation for ground-breaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the company's website, www.novavax.com .
Contact:
Novavax, Inc. Barclay A. Phillips SVP, Chief Financial Officer and Treasurer Andrea N. Flynn, Ph.D. Senior Manager, Investor Relations ir@novavax.com 240-268-2000 Russo Partners, LLC David Schull Todd Davenport, Ph.D. david.schull@russopartnersllc.com todd.davenport@russopartnersllc.com 212-845-4271
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Novavax, Inc. via GlobeNewswire
HUG#1943371
|
||||||||||||||||||
|
||||||||||||||||||
 | Back to overview list | |||||||||||||||||